This document provides methods and materials involved in depleting immunosuppressive monocytes (e.g., CD14+/DR− or CD14+/DRlow monocytes) within a mammal. For example, methods and materials involved in using a CD2 binding molecule (e.g., alefacept) to deplete immunosuppressive monocytes within a mammal (e.g., a human) are provided.
